Categories
Life Sciences Consumer Goods Materials and Chemicals Construction & Manufacturing Food and Beverages Energy and Power Semiconductor and Electronics Automotive and Transportation ICT & Media Aerospace & Defense BFSI

Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com

Wet Age-Related Macular Degeneration (AMD) Drugs Market by Type (LUCENTIS, AVASTIN, EYLEA, OTHER DRUGS) and by END USER (HOSPITALS, OPHTHALMIC CLINICS, RESEARCH INSTITUTES, CONTRACT RESEARCH ORGANIZATIONS): Global Opportunity Analysis and Industry Forecast, 2023-2032

A04483

Pages: NA

Charts: NA

Tables: NA

 Key Market Segments

  • By Type
    • LUCENTIS
    • AVASTIN
    • EYLEA
    • OTHER DRUGS
  • By END USER
    • HOSPITALS
    • OPHTHALMIC CLINICS
    • RESEARCH INSTITUTES
    • CONTRACT RESEARCH ORGANIZATIONS
  • By Region
    • North America
      • U.S.
      • Canada
      • Mexico
    • Europe
      • France
      • Germany
      • Italy
      • Spain
      • UK
      • Rest of Europe
    • Asia-Pacific
      • China
      • Japan
      • India
      • South Korea
      • Australia
      • Rest of Asia-Pacific
    • LAMEA
      • Brazil
      • South Africa
      • Saudi Arabia
      • Rest of LAMEA

 
Key Market Players

  • Pfizer Inc.
  • Sanofi
  • Novartis AG
  • Regeneron Pharmaceuticals Inc.
  • Santen Pharmaceutical Co. Ltd.
  • Ophthotech Corporation
  • Roche Holding AG
  • Genentech Inc.
  • Allergan plc
  • Bayer AG

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

  • CHAPTER 4: WET AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY TYPE

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Type

    • 4.2. LUCENTIS

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. AVASTIN

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

    • 4.4. EYLEA

      • 4.4.1. Key Market Trends, Growth Factors and Opportunities

      • 4.4.2. Market Size and Forecast, By Region

      • 4.4.3. Market Share Analysis, By Country

    • 4.5. OTHER DRUGS

      • 4.5.1. Key Market Trends, Growth Factors and Opportunities

      • 4.5.2. Market Size and Forecast, By Region

      • 4.5.3. Market Share Analysis, By Country

  • CHAPTER 5: WET AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY END USER

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By End User

    • 5.2. HOSPITALS

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. OPHTHALMIC CLINICS

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

    • 5.4. RESEARCH INSTITUTES

      • 5.4.1. Key Market Trends, Growth Factors and Opportunities

      • 5.4.2. Market Size and Forecast, By Region

      • 5.4.3. Market Share Analysis, By Country

    • 5.5. CONTRACT RESEARCH ORGANIZATIONS

      • 5.5.1. Key Market Trends, Growth Factors and Opportunities

      • 5.5.2. Market Size and Forecast, By Region

      • 5.5.3. Market Share Analysis, By Country

  • CHAPTER 6: WET AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY REGION

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By Region

    • 6.2. North America

      • 6.2.1. Key Market Trends and Opportunities

      • 6.2.2. Market Size and Forecast, By Type

      • 6.2.3. Market Size and Forecast, By End User

      • 6.2.4. Market Size and Forecast, By Country

      • 6.2.5. U.S. Wet Age-related Macular Degeneration (amd) Drugs Market

        • 6.2.5.1. Market Size and Forecast, By Type
        • 6.2.5.2. Market Size and Forecast, By End User

      • 6.2.6. Canada Wet Age-related Macular Degeneration (amd) Drugs Market

        • 6.2.6.1. Market Size and Forecast, By Type
        • 6.2.6.2. Market Size and Forecast, By End User

      • 6.2.7. Mexico Wet Age-related Macular Degeneration (amd) Drugs Market

        • 6.2.7.1. Market Size and Forecast, By Type
        • 6.2.7.2. Market Size and Forecast, By End User

    • 6.3. Europe

      • 6.3.1. Key Market Trends and Opportunities

      • 6.3.2. Market Size and Forecast, By Type

      • 6.3.3. Market Size and Forecast, By End User

      • 6.3.4. Market Size and Forecast, By Country

      • 6.3.5. France Wet Age-related Macular Degeneration (amd) Drugs Market

        • 6.3.5.1. Market Size and Forecast, By Type
        • 6.3.5.2. Market Size and Forecast, By End User

      • 6.3.6. Germany Wet Age-related Macular Degeneration (amd) Drugs Market

        • 6.3.6.1. Market Size and Forecast, By Type
        • 6.3.6.2. Market Size and Forecast, By End User

      • 6.3.7. Italy Wet Age-related Macular Degeneration (amd) Drugs Market

        • 6.3.7.1. Market Size and Forecast, By Type
        • 6.3.7.2. Market Size and Forecast, By End User

      • 6.3.8. Spain Wet Age-related Macular Degeneration (amd) Drugs Market

        • 6.3.8.1. Market Size and Forecast, By Type
        • 6.3.8.2. Market Size and Forecast, By End User

      • 6.3.9. UK Wet Age-related Macular Degeneration (amd) Drugs Market

        • 6.3.9.1. Market Size and Forecast, By Type
        • 6.3.9.2. Market Size and Forecast, By End User

      • 6.3.10. Russia Wet Age-related Macular Degeneration (amd) Drugs Market

        • 6.3.10.1. Market Size and Forecast, By Type
        • 6.3.10.2. Market Size and Forecast, By End User

      • 6.3.11. Rest Of Europe Wet Age-related Macular Degeneration (amd) Drugs Market

        • 6.3.11.1. Market Size and Forecast, By Type
        • 6.3.11.2. Market Size and Forecast, By End User

    • 6.4. Asia-Pacific

      • 6.4.1. Key Market Trends and Opportunities

      • 6.4.2. Market Size and Forecast, By Type

      • 6.4.3. Market Size and Forecast, By End User

      • 6.4.4. Market Size and Forecast, By Country

      • 6.4.5. China Wet Age-related Macular Degeneration (amd) Drugs Market

        • 6.4.5.1. Market Size and Forecast, By Type
        • 6.4.5.2. Market Size and Forecast, By End User

      • 6.4.6. Japan Wet Age-related Macular Degeneration (amd) Drugs Market

        • 6.4.6.1. Market Size and Forecast, By Type
        • 6.4.6.2. Market Size and Forecast, By End User

      • 6.4.7. India Wet Age-related Macular Degeneration (amd) Drugs Market

        • 6.4.7.1. Market Size and Forecast, By Type
        • 6.4.7.2. Market Size and Forecast, By End User

      • 6.4.8. South Korea Wet Age-related Macular Degeneration (amd) Drugs Market

        • 6.4.8.1. Market Size and Forecast, By Type
        • 6.4.8.2. Market Size and Forecast, By End User

      • 6.4.9. Australia Wet Age-related Macular Degeneration (amd) Drugs Market

        • 6.4.9.1. Market Size and Forecast, By Type
        • 6.4.9.2. Market Size and Forecast, By End User

      • 6.4.10. Thailand Wet Age-related Macular Degeneration (amd) Drugs Market

        • 6.4.10.1. Market Size and Forecast, By Type
        • 6.4.10.2. Market Size and Forecast, By End User

      • 6.4.11. Malaysia Wet Age-related Macular Degeneration (amd) Drugs Market

        • 6.4.11.1. Market Size and Forecast, By Type
        • 6.4.11.2. Market Size and Forecast, By End User

      • 6.4.12. Indonesia Wet Age-related Macular Degeneration (amd) Drugs Market

        • 6.4.12.1. Market Size and Forecast, By Type
        • 6.4.12.2. Market Size and Forecast, By End User

      • 6.4.13. Rest of Asia Pacific Wet Age-related Macular Degeneration (amd) Drugs Market

        • 6.4.13.1. Market Size and Forecast, By Type
        • 6.4.13.2. Market Size and Forecast, By End User

    • 6.5. LAMEA

      • 6.5.1. Key Market Trends and Opportunities

      • 6.5.2. Market Size and Forecast, By Type

      • 6.5.3. Market Size and Forecast, By End User

      • 6.5.4. Market Size and Forecast, By Country

      • 6.5.5. Brazil Wet Age-related Macular Degeneration (amd) Drugs Market

        • 6.5.5.1. Market Size and Forecast, By Type
        • 6.5.5.2. Market Size and Forecast, By End User

      • 6.5.6. South Africa Wet Age-related Macular Degeneration (amd) Drugs Market

        • 6.5.6.1. Market Size and Forecast, By Type
        • 6.5.6.2. Market Size and Forecast, By End User

      • 6.5.7. Saudi Arabia Wet Age-related Macular Degeneration (amd) Drugs Market

        • 6.5.7.1. Market Size and Forecast, By Type
        • 6.5.7.2. Market Size and Forecast, By End User

      • 6.5.8. UAE Wet Age-related Macular Degeneration (amd) Drugs Market

        • 6.5.8.1. Market Size and Forecast, By Type
        • 6.5.8.2. Market Size and Forecast, By End User

      • 6.5.9. Argentina Wet Age-related Macular Degeneration (amd) Drugs Market

        • 6.5.9.1. Market Size and Forecast, By Type
        • 6.5.9.2. Market Size and Forecast, By End User

      • 6.5.10. Rest of LAMEA Wet Age-related Macular Degeneration (amd) Drugs Market

        • 6.5.10.1. Market Size and Forecast, By Type
        • 6.5.10.2. Market Size and Forecast, By End User

  • CHAPTER 7: COMPETITIVE LANDSCAPE

    • 7.1. Introduction

    • 7.2. Top Winning Strategies

    • 7.3. Product Mapping Of Top 10 Player

    • 7.4. Competitive Dashboard

    • 7.5. Competitive Heatmap

    • 7.6. Top Player Positioning, 2024

  • CHAPTER 8: COMPANY PROFILES

    • 8.1. Regeneron Pharmaceuticals Inc.

      • 8.1.1. Company Overview

      • 8.1.2. Key Executives

      • 8.1.3. Company Snapshot

      • 8.1.4. Operating Business Segments

      • 8.1.5. Product Portfolio

      • 8.1.6. Business Performance

      • 8.1.7. Key Strategic Moves and Developments

    • 8.2. Novartis AG

      • 8.2.1. Company Overview

      • 8.2.2. Key Executives

      • 8.2.3. Company Snapshot

      • 8.2.4. Operating Business Segments

      • 8.2.5. Product Portfolio

      • 8.2.6. Business Performance

      • 8.2.7. Key Strategic Moves and Developments

    • 8.3. Roche Holding AG

      • 8.3.1. Company Overview

      • 8.3.2. Key Executives

      • 8.3.3. Company Snapshot

      • 8.3.4. Operating Business Segments

      • 8.3.5. Product Portfolio

      • 8.3.6. Business Performance

      • 8.3.7. Key Strategic Moves and Developments

    • 8.4. Genentech Inc.

      • 8.4.1. Company Overview

      • 8.4.2. Key Executives

      • 8.4.3. Company Snapshot

      • 8.4.4. Operating Business Segments

      • 8.4.5. Product Portfolio

      • 8.4.6. Business Performance

      • 8.4.7. Key Strategic Moves and Developments

    • 8.5. Santen Pharmaceutical Co. Ltd.

      • 8.5.1. Company Overview

      • 8.5.2. Key Executives

      • 8.5.3. Company Snapshot

      • 8.5.4. Operating Business Segments

      • 8.5.5. Product Portfolio

      • 8.5.6. Business Performance

      • 8.5.7. Key Strategic Moves and Developments

    • 8.6. Pfizer Inc.

      • 8.6.1. Company Overview

      • 8.6.2. Key Executives

      • 8.6.3. Company Snapshot

      • 8.6.4. Operating Business Segments

      • 8.6.5. Product Portfolio

      • 8.6.6. Business Performance

      • 8.6.7. Key Strategic Moves and Developments

    • 8.7. Sanofi

      • 8.7.1. Company Overview

      • 8.7.2. Key Executives

      • 8.7.3. Company Snapshot

      • 8.7.4. Operating Business Segments

      • 8.7.5. Product Portfolio

      • 8.7.6. Business Performance

      • 8.7.7. Key Strategic Moves and Developments

    • 8.8. Bayer AG

      • 8.8.1. Company Overview

      • 8.8.2. Key Executives

      • 8.8.3. Company Snapshot

      • 8.8.4. Operating Business Segments

      • 8.8.5. Product Portfolio

      • 8.8.6. Business Performance

      • 8.8.7. Key Strategic Moves and Developments

    • 8.9. Allergan Plc

      • 8.9.1. Company Overview

      • 8.9.2. Key Executives

      • 8.9.3. Company Snapshot

      • 8.9.4. Operating Business Segments

      • 8.9.5. Product Portfolio

      • 8.9.6. Business Performance

      • 8.9.7. Key Strategic Moves and Developments

    • 8.10. Ophthotech Corporation

      • 8.10.1. Company Overview

      • 8.10.2. Key Executives

      • 8.10.3. Company Snapshot

      • 8.10.4. Operating Business Segments

      • 8.10.5. Product Portfolio

      • 8.10.6. Business Performance

      • 8.10.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL WET AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 2. GLOBAL WET AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR LUCENTIS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 3. GLOBAL WET AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR AVASTIN, BY REGION, 2025-2033 ($MILLION)
  • TABLE 4. GLOBAL WET AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR EYLEA, BY REGION, 2025-2033 ($MILLION)
  • TABLE 5. GLOBAL WET AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR OTHER DRUGS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 6. GLOBAL WET AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY END USER, 2025-2033 ($MILLION)
  • TABLE 7. GLOBAL WET AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR HOSPITALS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 8. GLOBAL WET AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR OPHTHALMIC CLINICS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 9. GLOBAL WET AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR RESEARCH INSTITUTES, BY REGION, 2025-2033 ($MILLION)
  • TABLE 10. GLOBAL WET AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 11. GLOBAL WET AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY REGION, 2025-2033 ($MILLION)
  • TABLE 12. NORTH AMERICA WET AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 13. NORTH AMERICA WET AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 14. NORTH AMERICA WET AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 15. U.S. WET AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 16. U.S. WET AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 17. CANADA WET AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 18. CANADA WET AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 19. MEXICO WET AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 20. MEXICO WET AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 21. EUROPE WET AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 22. EUROPE WET AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 23. EUROPE WET AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 24. FRANCE WET AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 25. FRANCE WET AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 26. GERMANY WET AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 27. GERMANY WET AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 28. ITALY WET AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 29. ITALY WET AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 30. SPAIN WET AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 31. SPAIN WET AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 32. UK WET AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 33. UK WET AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 34. RUSSIA WET AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 35. RUSSIA WET AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 36. REST OF EUROPE WET AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 37. REST OF EUROPE WET AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 38. ASIA-PACIFIC WET AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 39. ASIA-PACIFIC WET AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 40. ASIA-PACIFIC WET AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 41. CHINA WET AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 42. CHINA WET AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 43. JAPAN WET AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 44. JAPAN WET AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 45. INDIA WET AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 46. INDIA WET AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 47. SOUTH KOREA WET AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 48. SOUTH KOREA WET AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 49. AUSTRALIA WET AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 50. AUSTRALIA WET AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 51. THAILAND WET AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 52. THAILAND WET AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 53. MALAYSIA WET AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 54. MALAYSIA WET AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 55. INDONESIA WET AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 56. INDONESIA WET AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 57. REST OF ASIA PACIFIC WET AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 58. REST OF ASIA PACIFIC WET AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 59. LAMEA WET AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 60. LAMEA WET AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 61. LAMEA WET AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 62. BRAZIL WET AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 63. BRAZIL WET AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 64. SOUTH AFRICA WET AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 65. SOUTH AFRICA WET AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 66. SAUDI ARABIA WET AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 67. SAUDI ARABIA WET AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 68. UAE WET AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 69. UAE WET AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 70. ARGENTINA WET AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 71. ARGENTINA WET AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 72. REST OF LAMEA WET AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 73. REST OF LAMEA WET AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 74. REGENERON PHARMACEUTICALS INC.: KEY EXECUTIVES
  • TABLE 75. REGENERON PHARMACEUTICALS INC.: COMPANY SNAPSHOT
  • TABLE 76. REGENERON PHARMACEUTICALS INC.: OPERATING SEGMENTS
  • TABLE 77. REGENERON PHARMACEUTICALS INC.: PRODUCT PORTFOLIO
  • TABLE 78. REGENERON PHARMACEUTICALS INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 79. NOVARTIS AG: KEY EXECUTIVES
  • TABLE 80. NOVARTIS AG: COMPANY SNAPSHOT
  • TABLE 81. NOVARTIS AG: OPERATING SEGMENTS
  • TABLE 82. NOVARTIS AG: PRODUCT PORTFOLIO
  • TABLE 83. NOVARTIS AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 84. ROCHE HOLDING AG: KEY EXECUTIVES
  • TABLE 85. ROCHE HOLDING AG: COMPANY SNAPSHOT
  • TABLE 86. ROCHE HOLDING AG: OPERATING SEGMENTS
  • TABLE 87. ROCHE HOLDING AG: PRODUCT PORTFOLIO
  • TABLE 88. ROCHE HOLDING AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 89. GENENTECH INC.: KEY EXECUTIVES
  • TABLE 90. GENENTECH INC.: COMPANY SNAPSHOT
  • TABLE 91. GENENTECH INC.: OPERATING SEGMENTS
  • TABLE 92. GENENTECH INC.: PRODUCT PORTFOLIO
  • TABLE 93. GENENTECH INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 94. SANTEN PHARMACEUTICAL CO. LTD.: KEY EXECUTIVES
  • TABLE 95. SANTEN PHARMACEUTICAL CO. LTD.: COMPANY SNAPSHOT
  • TABLE 96. SANTEN PHARMACEUTICAL CO. LTD.: OPERATING SEGMENTS
  • TABLE 97. SANTEN PHARMACEUTICAL CO. LTD.: PRODUCT PORTFOLIO
  • TABLE 98. SANTEN PHARMACEUTICAL CO. LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 99. PFIZER INC.: KEY EXECUTIVES
  • TABLE 100. PFIZER INC.: COMPANY SNAPSHOT
  • TABLE 101. PFIZER INC.: OPERATING SEGMENTS
  • TABLE 102. PFIZER INC.: PRODUCT PORTFOLIO
  • TABLE 103. PFIZER INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 104. SANOFI: KEY EXECUTIVES
  • TABLE 105. SANOFI: COMPANY SNAPSHOT
  • TABLE 106. SANOFI: OPERATING SEGMENTS
  • TABLE 107. SANOFI: PRODUCT PORTFOLIO
  • TABLE 108. SANOFI: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 109. BAYER AG: KEY EXECUTIVES
  • TABLE 110. BAYER AG: COMPANY SNAPSHOT
  • TABLE 111. BAYER AG: OPERATING SEGMENTS
  • TABLE 112. BAYER AG: PRODUCT PORTFOLIO
  • TABLE 113. BAYER AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 114. ALLERGAN PLC: KEY EXECUTIVES
  • TABLE 115. ALLERGAN PLC: COMPANY SNAPSHOT
  • TABLE 116. ALLERGAN PLC: OPERATING SEGMENTS
  • TABLE 117. ALLERGAN PLC: PRODUCT PORTFOLIO
  • TABLE 118. ALLERGAN PLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 119. OPHTHOTECH CORPORATION: KEY EXECUTIVES
  • TABLE 120. OPHTHOTECH CORPORATION: COMPANY SNAPSHOT
  • TABLE 121. OPHTHOTECH CORPORATION: OPERATING SEGMENTS
  • TABLE 122. OPHTHOTECH CORPORATION: PRODUCT PORTFOLIO
  • TABLE 123. OPHTHOTECH CORPORATION: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL WET AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET SEGMENTATION
  • FIGURE 2. GLOBAL WET AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET
  • FIGURE 3. SEGMENTATION WET AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN WET AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALWET AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET
  • FIGURE 11. WET AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET SEGMENTATION, BY BY TYPE
  • FIGURE 12. WET AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR LUCENTIS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 13. WET AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR AVASTIN, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 14. WET AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR EYLEA, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 15. WET AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR OTHER DRUGS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 16. WET AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET SEGMENTATION, BY BY END USER
  • FIGURE 17. WET AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR HOSPITALS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 18. WET AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR OPHTHALMIC CLINICS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 19. WET AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR RESEARCH INSTITUTES, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 20. WET AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 21. TOP WINNING STRATEGIES, BY YEAR, 2022-2024*
  • FIGURE 22. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2022-2024*
  • FIGURE 23. TOP WINNING STRATEGIES, BY COMPANY, 2022-2024*
  • FIGURE 24. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 25. COMPETITIVE DASHBOARD
  • FIGURE 26. COMPETITIVE HEATMAP: WET AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET
  • FIGURE 27. TOP PLAYER POSITIONING, 2024
  • FIGURE 28. REGENERON PHARMACEUTICALS INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 29. REGENERON PHARMACEUTICALS INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 30. REGENERON PHARMACEUTICALS INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 31. NOVARTIS AG: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 32. NOVARTIS AG: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 33. NOVARTIS AG: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 34. ROCHE HOLDING AG: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 35. ROCHE HOLDING AG: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 36. ROCHE HOLDING AG: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 37. GENENTECH INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 38. GENENTECH INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 39. GENENTECH INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 40. SANTEN PHARMACEUTICAL CO. LTD.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 41. SANTEN PHARMACEUTICAL CO. LTD.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 42. SANTEN PHARMACEUTICAL CO. LTD.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 43. PFIZER INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 44. PFIZER INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 45. PFIZER INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 46. SANOFI: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 47. SANOFI: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 48. SANOFI: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 49. BAYER AG: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 50. BAYER AG: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 51. BAYER AG: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 52. ALLERGAN PLC: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 53. ALLERGAN PLC: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 54. ALLERGAN PLC: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 55. OPHTHOTECH CORPORATION: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 56. OPHTHOTECH CORPORATION: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 57. OPHTHOTECH CORPORATION: REVENUE SHARE, BY REGION, 2024 (%)

Purchase Full Report of
Wet Age-Related Macular Degeneration (AMD) Drugs Market

PURCHASE OPTIONS



* Taxes/Fees, If applicable will be added during checkout. All prices in USD.

Have a question ?

Need to add more ?

Avail up to 30% discount on subscription plans on


Avenue

© 2025 Allied Market Research. All Rights Reserved